Cabaletta Bio to Participate in the Cowen Virtual 42nd Annual Health Care Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cabaletta Bio, a clinical-stage biotechnology company focused on targeted cell therapies for autoimmune diseases, announced that CEO Steven Nichtberger will join the Neuromuscular corporate panel at the Cowen Virtual 42nd Annual Health Care Conference on March 7, 2022, at 9:10 a.m. ET.
A live webcast will be accessible on the company's website, with replays available for 30 days. Cabaletta Bio's innovative CABA platform aims to develop therapies for conditions like pemphigus vulgaris and myasthenia gravis, positioning the company at the forefront of biotechnological advancements in autoimmune treatment.
Details
News Market Reaction – CABA
The recorded move for CABA in the trading session of this news was -0.92%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PHILADELPHIA, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in the Neuromuscular corporate panel discussion at the Cowen Virtual 42nd Annual Health Care Conference on Monday, March 7, 2022, at 9:10 a.m. ET.
A live webcast of the panel will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays of the webcast will be available on the website for 30 days.
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform, in combination with Cabaletta Bio’s proprietary technology, has advanced a growing pipeline that currently includes potential treatments for patients with mucosal pemphigus vulgaris, MuSK-associated myasthenia gravis, PLA2R-associated membranous nephropathy, mucocutaneous pemphigus vulgaris and hemophilia A with FVIII alloantibodies. Cabaletta Bio’s headquarters are located in Philadelphia, PA. For more information, visit www.cabalettabio.com and follow us on LinkedIn.
Contacts:
Anup Marda
Chief Financial Officer
investors@cabalettabio.com
Sarah McCabe
Stern Investor Relations, Inc.
sarah.mccabe@sternir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.